Failure To Warn Of PTC/IIH Risks from Mirena IUD Result in Lawsuit Against Bayer

According to allegations raised in a lawsuit filed against Bayer Healthcare, the drug maker failed to adequately warn about the potential side effects of the Mirena IUD, including the risk that women who receive the birth control implant may develop a medical condition known as pseudotumor cerebri (PTC), which is also sometimes referred to as idiopathic intracranial hypertension (IIH).

The complaint (PDF) was filed by Jessica Gardner in the U.S. District Court for the District of New Jersey on February 19, indicating that the failure to warn about the PTC/IIH risks associated with Mirena left her with severe vision problems and permanent optic nerve damage.

Pseudotumor cerebri (PTC) is a dangerous medical emergency caused by a buildup of fluid pressure in the skull. This can cause severe headaches, vision problems and result in permanent damage to the optic nerve, even after the fluid pressure has been relieved.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Gardner indicates that she received the Mirena IUD in April 2013, which involves a T-shaped implant placed in the uterus to prevent pregnancy for up to five years. The device releases the progestin levonorgestrel, which is also used in other birth control products, and has previously been linked to a risk of PTC/IIH.

The lawsuit indicates that after Gardner had the Mirena IUD placed in her body, she began to suffer intense headaches, blurred vision, double vision and dizziness. She was diagnosed with papilledema in February 2014, which doctors later determined was caused by PTC/IIH from the Mirena implant.

“Mirena’s label makes no mention of PTC/IIH, despite a known link between levonorgestrel and PTC/IIH,’ the lawsuit states. “Defendants also provide a ‘Patient Information Booklet’ to physicians to be given to patients at the time of Mirena insertion. Defendants’ Mirena ‘Patient Information Booklet’ also makes no mention of PTC/IIH, despite a known link between levonorgestrel and PTC/IIH.”

The case joins a growing number of Mirena PTC/IIH lawsuits filed in recent years, each raising similar allegations that plaintiffs may have avoided severe and potentially life-long problems from permanent optic nerve damage if the drug maker had provided warnings about the importance of removing the device once symptoms first appeared.

Given similar questions of fact and law raised in complaints filed in U.S. District Courts nationwide, a petition was filed earlier this month to centralize and consolidate the Mirena litigation before one judge for coordinated management as part of a federal MDL, or multidistrict litigation.

Although a prior request to centralize the cases was rejected several years ago, with more than 100 complaints filed by women with PTC/IIH, it is expected that the U.S. Judicial Panel on Multidistrict Litigation (JPML) will determine that centralization is now appropriate.

If a Mirena MDL is established for the PTC/IIH cases, Gardner’s complaint will be transferred to the centralized proceedings. However, if Mirena settlements are not reached following bellwether trials and the MDL process, her case may be remanded back to federal court in Missouri for an individual trial date.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

MDL Judge Schedules Ozempic Lawsuit Status Conferences Throughout 2025
MDL Judge Schedules Ozempic Lawsuit Status Conferences Throughout 2025 (Posted today)

With the first Ozempic lawsuit bellwether trials not expected to begin until at least late 2026 or early 2027, the court will address motions to dismiss and other “cross cutting” issues in 2025.